From the November 1999 Idaho Observer:

FDA indicts naturopath in LDC investigation

PORTLAND -- Oregon naturopath Clyde Reynolds, 73, was arraigned November 5, 1999, in Florida Federal Court for his participation in what the FDA considers a conspiracy to make an unapproved drug available to the public.

Reynolds has been charged with two counts tantamount to labeling violations for his insistence upon making sure that his patients and victims of Parkinson's disease have access to Liquid Deprenyl Citrate (LDC). Reynolds, who successfully treats 94 percent of his cancer patients and has never had any of his patients complain about his use of LDC or any of the other effective yet unorthodox therapies he employs, is facing 15 years in prison if found guilty.

LDC is a nutritive substance derived from the ephedra plant that simply boosts the body's ability to produce dopamine so that it may have the tools to combat the ravages of degenerative diseases such as Parkinsons and cancer.

Ranking FDA Office of Criminal Investigations official Don Liggett, a man who has been party to the FDA persecution of Discovery Experimental and Development, Inc. (DEDI) since the Florida company developed LDC in 1990, admitted to The Idaho Observer that he is not aware of even one incident where LDC has been reported to have caused an adverse reaction, nor is he aware of even one consumer complaint regarding the use of LDC.

Liggett admitted that the FDA's case against LDC is purely administrative. "The system, like many systems...is not an easy system to deal with for the small-time operation...the majority of firms that have drugs approved in the United States are international in scope...and fantastically wealthy and able to invest the resources..."

LDC is a marketplace competitor for FDA-approved Eldepryl, manufactured by Somerset Pharmaceuticals. The U.S. Pharmacological Conference tested Eldepryl and determined it be contaminated with methamphetamine and a publicly unidentified neurotoxin that were causing dire consequences in many Eledpryl users.

Dr. Reynolds had been legally making LDC available to people through a buyer's club as an over the counter substance until September when FDA Special Agent Rande Matteson seized a shipment bound for England. Since then, customer supplies of LDC are being used up and they are currently unable to replenish their supplies. Dr. Reynolds believes that 600 to 1,000 people are going to die over FDA LDC policy. Marvin Rosenthal, whose father was diagnosed with Parkinson's in 1982 and was almost dead by 1990 after taking Eldepryl, is desperate to find LDC for his father because he believes that he will die without it.

FDA LDC policy is consistent with many cases where the federal agency uses its authority to block public access to effective medicines and are manufactured by companies that are unable or unwilling to spend the estimated $230 million of graft it takes to achieve FDA approval for a new drug.